Related Experiment Videos
Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical
1University of California San Francisco Comprehensive Cancer Center, 2nd Floor BCC, 1600 Divisidero Street, San Francisco, CA 94115, USA. mman@itsa.ucsf.edu
Idrugs : the Investigational Drugs Journal
|August 25, 2005
Abstract:
Cell Therapeutics Inc, under license from the MD Anderson Cancer Center and in collaboration with Chugai Pharmaceutical Co Ltd (the Japanese subsidiary of Roche), is developing paclitaxel poliglumex, an intravenous poly-(alpha-L-glutamic acid) conjugate of paclitaxel for the potential treatment of solid tumors.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...